Related Experiment Video
Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
1Christian Medical College and Hospital, Ludhiana, Punjab, India.
Auranofin-loaded nanoparticles effectively protected against aluminum chloride-induced Alzheimer's disease in rats. These nanoparticles demonstrated superior neuroprotective potential compared to auranofin alone, offering a promising therapeutic strategy.
Area of Science:
- Neuroscience
- Nanotechnology
- Pharmacology
Background:
- Central nervous system (CNS) disorder treatments are limited, with the blood-brain barrier (BBB) posing a significant challenge.
- Nanoformulation approaches enhance drug delivery across the BBB for CNS disorders.
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options.
Purpose of the Study:
- To evaluate the neuroprotective effects of auranofin-loaded poly (lactic-co-glycolic acid) nanoparticles (AF-PLGA NPs).
- To assess the efficacy of AF-PLGA NPs against aluminum chloride (AlCl3)-induced Alzheimer's disease model in rats.
Main Methods:
- Auranofin-loaded PLGA nanoparticles (AF-PLGA NPs) were synthesized and characterized for entrapment efficiency, particle size, surface charge, and morphology.
- Rats were induced with Alzheimer's disease using AlCl3.
- Animals were treated with auranofin (AF) or AF-PLGA NPs, and hippocampus tissues were analyzed for biochemical and neuroinflammatory markers.
Main Results:
- AF-PLGA NPs exhibited high entrapment efficiency (98%) and optimal particle size (319.8±16.5 nm).
- Both AF and AF-PLGA NPs significantly reversed cognitive deficits and neuroinflammation induced by AlCl3.
- AF-PLGA NPs demonstrated enhanced neuroprotective efficacy compared to AF alone.
Conclusions:
- AF-PLGA nanoparticles offer significant therapeutic benefits for Alzheimer's disease, attributed to Auranofin's antioxidant and anti-inflammatory properties.
- The modulation of particle size in nanoformulations enhances therapeutic outcomes.
- AF-PLGA NPs represent a potential therapeutic candidate for managing Alzheimer's disease.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation